Can-Fite BioPharma (CANF) Revenue (2015 - 2023)

Can-Fite BioPharma (CANF) has 9 years of Revenue data on file, last reported at $155000.0 in Q4 2023.

• For the quarter ending Q4 2023, Revenue rose 19.23% year-over-year to $155000.0; the trailing twelve-month figure through Dec 2023 stood at $743000.0 (changed 0.0% YoY), and the FY2025 full-year result was $405000.0, down 39.91% from the prior year.
• Revenue was $155000.0 for Q4 2023 at Can-Fite BioPharma, down from $196000.0 in the prior quarter.
• In the past five years, Revenue ranged from a high of $1.2 million in Q3 2019 to a low of $130000.0 in Q4 2022.
• A 5-year average of $259789.5 and a median of $204000.0 in 2020 frame the typical range for Revenue.
• Across the five-year window, Revenue soared 44.07% in 2019 and plunged 81.68% in 2020, its largest moves.
• Can-Fite BioPharma's Revenue stood at $192000.0 in 2019, then decreased by 21.88% to $150000.0 in 2020, then soared by 36.0% to $204000.0 in 2021, then plunged by 36.27% to $130000.0 in 2022, then climbed by 19.23% to $155000.0 in 2023.
• Per Business Quant data, the three most recent Revenue figures were $155000.0 in Q4 2023, $196000.0 in Q3 2023, and $196000.0 in Q2 2023.